Close Menu

NMPA

Beijing-based China Medical Technologies said this week that China's State Food and Drug Administration has approved its real-time PCR-based KRAS assay as a companion diagnostic test for the use of a targeted colorectal cancer drug.

NEW YORK (GenomeWeb News) – China Medical Technologies today announced that its PCR-based KRAS assay has been approved in China as a companion diagnostic for an undisclosed drug targeting colorectal cancer.

BGI, which, according to an official, generated roughly $6.2 million in proteomics revenue last year, plans to buy around 15 new high-resolution machines and 30 to 40 triple quadrupoles as part of its efforts to expand into the clinical proteomics and pharma markets.

The approval from SFDA will help the company increase its market presence in China where the IVD market is estimated at $2 billion per year.

China's State Food and Drug Administration granted approval for its EGFR and BRAF tests for clinical use.

According to the company, the kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

Gen-Probe launches Elucigene KRAS.BRAF kit; China Medical Technologies gets Chinese approval for EGFR assay.

China's food and drug regulator has cleared two microarray tests and an amplification test for identifying and differentiating tuberculosis.

Pages

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.